Q4 EPS Estimate for Pacira BioSciences Lifted by Analyst

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Research analysts at HC Wainwright increased their Q4 2026 EPS estimates for Pacira BioSciences in a research note issued to investors on Wednesday, August 5th. HC Wainwright analyst D. Tsao now forecasts that the company will earn $0.68 per share for the quarter, up from their previous estimate of $0.64. HC Wainwright currently has a “Buy” rating and a $38.00 target price on the stock. The consensus estimate for Pacira BioSciences’ current full-year earnings is $1.94 per share.

Other equities research analysts also recently issued research reports about the company. Needham & Company LLC increased their price objective on Pacira BioSciences from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Wall Street Zen upgraded shares of Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a report on Saturday. Weiss Ratings raised shares of Pacira BioSciences from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, May 20th. Finally, Royal Bank Of Canada lifted their price target on Pacira BioSciences from $24.00 to $25.00 and gave the company a “sector perform” rating in a report on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Pacira BioSciences currently has an average rating of “Hold” and an average price target of $29.80.

Pacira BioSciences Stock Performance

Shares of NASDAQ PCRX opened at $24.43 on Tuesday. Pacira BioSciences has a 1 year low of $18.80 and a 1 year high of $27.66. The firm has a market cap of $973.78 million, a P/E ratio of 69.80 and a beta of 0.27. The stock has a fifty day moving average price of $24.72 and a two-hundred day moving average price of $23.47. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.94 and a current ratio of 5.04.

Pacira BioSciences (NASDAQ:PCRX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.65 by $0.08. The business had revenue of $192.40 million during the quarter, compared to analyst estimates of $191.06 million. Pacira BioSciences had a net margin of 1.96% and a return on equity of 9.68%. The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.74 EPS.

Insider Activity

In related news, SVP Lauren Riker sold 6,115 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $23.50, for a total transaction of $143,702.50. Following the completion of the sale, the senior vice president directly owned 62,284 shares of the company’s stock, valued at $1,463,674. This trade represents a 8.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.40% of the company’s stock.

Institutional Trading of Pacira BioSciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its stake in Pacira BioSciences by 15.1% in the first quarter. PNC Financial Services Group Inc. now owns 3,751 shares of the company’s stock valued at $85,000 after buying an additional 492 shares during the period. Inspire Investing LLC grew its holdings in shares of Pacira BioSciences by 3.2% during the fourth quarter. Inspire Investing LLC now owns 17,958 shares of the company’s stock worth $465,000 after buying an additional 556 shares in the last quarter. State of Wyoming grew its stake in shares of Pacira BioSciences by 7.0% during the 4th quarter. State of Wyoming now owns 11,155 shares of the company’s stock worth $289,000 after acquiring an additional 728 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in Pacira BioSciences by 8.0% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 10,604 shares of the company’s stock valued at $259,000 after purchasing an additional 785 shares in the last quarter. Finally, Franklin Resources Inc. grew its holdings in shares of Pacira BioSciences by 2.6% in the 4th quarter. Franklin Resources Inc. now owns 33,860 shares of the company’s stock valued at $876,000 after acquiring an additional 846 shares in the last quarter. 99.73% of the stock is owned by institutional investors.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.